Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.solara.co.in | |
Market Cap | 1,340.68 Cr. | |
Enterprise Value(EV) | 2,307.16 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -85.64 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 41.54 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 330.06 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.13 | Calculated using Price: 372.45 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 3.60 Cr. | 35,996,267 Shares |
FaceValue | 10 | |
About Solara Active Pharma Sciences Ltd. | ||
Solara Active Pharma Sciences is a dynamic, entrepreneurial and customer-oriented API manufacturer. It has a legacy of over three decades and trace its origins to the API expertise of Strides Shasun Ltd. and the technical know-how of human API business from Sequent Scientific Ltd. The company is a global, R&D focused, pureplay API company engaged in the manufacturing and development of APIs and offering Contract Manufacturing and Development Services for global companies. |
1 Day |
|
-1.88% |
1 Week |
|
+0.11% |
1 Month |
|
-18.40% |
3 Month |
|
+1.86% |
6 Month |
|
+5.09% |
1 Year |
|
+8.73% |
2 Year |
|
-45.95% |
5 Year |
|
-9.71% |
10 Year |
|
6 years | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 0.78 | 8.32 | 12.48 | 17.23 | -3.75 | -1.47 | |
Return on Capital Employed (%) | 2.22 | 10.38 | 11.73 | 15.34 | -0.67 | 1.79 | |
Return on Assets (%) | 0.33 | 3.55 | 5.57 | 9.34 | -2.13 | -0.78 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 764 | 956 | 1,086 | 1,589 | 1,525 | 1,500 | 1,463 | |
Non Curr. Liab. | 315 | 344 | 333 | 206 | 299 | 217 | 155 | |
Curr. Liab. | 738 | 656 | 730 | 789 | 1,063 | 1,101 | 1,165 | |
Minority Int. | 4 | 4 | 4 | 4 | 2 | 2 | 3 | |
Equity & Liab. | 1,821 | 1,960 | 2,153 | 2,588 | 2,890 | 2,821 | 2,787 | |
Non Curr. Assets | 1,214 | 1,312 | 1,481 | 1,530 | 1,651 | 1,633 | 1,592 | |
Curr. Assets | 608 | 648 | 672 | 1,058 | 1,239 | 1,188 | 1,195 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 1,821 | 1,960 | 2,153 | 2,588 | 2,890 | 2,821 | 2,787 |
Particulars | 7 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 521 | 1,387 | 1,322 | 1,617 | 1,268 | 1,444 | 1,407 | |
Other Income | 2 | 12 | 28 | 29 | 20 | 23 | 8 | |
Total Income | 523 | 1,399 | 1,349 | 1,646 | 1,288 | 1,466 | 1,415 | |
Total Expenditure | -458 | -1,166 | -1,062 | -1,231 | -1,188 | -1,310 | -1,463 | |
PBIDT | 65 | 233 | 287 | 415 | 100 | 156 | -48 | |
Interest | -25 | -82 | -78 | -84 | -75 | -90 | -96 | |
Depreciation | -34 | -83 | -94 | -109 | -112 | -111 | -105 | |
Taxation | 0 | -1 | 0 | 0 | 33 | 23 | 9 | |
Exceptional Items | -3 | -68 | ||||||
PAT | 6 | 67 | 115 | 221 | -58 | -22 | -308 | |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | -1 | |
Share Associate | ||||||||
Other Related Items | ||||||||
Consolidated Net Profit | 0 | 60 | 115 | 221 | -58 | -22 | -308 | |
Adjusted EPS | 0 | 23 | 43 | 62 | -16 | -6 | -86 |
Particulars | 6 years | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 49 | 166 | 242 | 155 | -242 | 156 | |
Cash Fr. Inv. | -85 | -116 | -359 | -106 | -243 | -81 | |
Cash Fr. Finan. | 68 | -23 | 97 | 92 | 334 | -113 | |
Net Change | 31 | 27 | -20 | 142 | -151 | -38 | |
Cash & Cash Eqvt | 46 | 76 | 56 | 198 | 46 | 9 |
Thu, 28 Mar 2024
''Update On Transfer Of 100% Shareholding In Wholly Owned Subsidiary Company''. Update on Transfer of 100% shareholding in Wholly Owned Subsidiary Company. |
Wed, 27 Mar 2024
Closure of Trading Window Closure of Trading Window |
Mon, 25 Mar 2024
Sale Of 100% Shareholding In The Wholly Owned Subsidiary Company - Sequent Penems Private Limited. Sale of 100% shareholding in the Wholly Owned Subsidiary Company - Sequent Penems Private Limited. |
Thu, 28 Mar 2024 |
High Decrease in 1 Month |
Closing Near 200 SMA |
Close Crossing 200 SMA From Above |
Wed, 27 Mar 2024 |
Making Lower Lows for 2 Days |
High Decrease in 1 Month |